50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Buy Alert For $2 Coin (Ad)pixel
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Buy Alert For $2 Coin (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Finally... Some Good News (Ad)pixel
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:IOVA

Iovance Biotherapeutics - IOVA Stock Forecast, Price & News

$9.79
-0.26 (-2.59%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.50
$10.00
50-Day Range
$9.79
$13.05
52-Week Range
$6.18
$27.96
Volume
2.12 million shs
Average Volume
2.08 million shs
Market Capitalization
$1.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.80

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
143.1% Upside
$23.80 Price Target
Short Interest
Healthy
13.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.53) to ($2.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

741st out of 1,080 stocks

Biological Products, Except Diagnostic Industry

123rd out of 172 stocks

IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

IOVA Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics to Present Posters at ESMO 2022
Expert Ratings for Iovance Biotherapeutics
Iovance: TIL Cell Therapy Set To Prove Itself
7 Analysts Have This to Say About Iovance Biotherapeutics
Why Iovance Biotherapeutics Was Halved Today
Iovance: Onward To Approval
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
8/04/2022
Today
9/24/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
319
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.80
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+143.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-342,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
145,223,000
Market Cap
$1.54 billion
Optionable
Optionable
Beta
0.50

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 48)
    J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
    Comp: $752.81k
  • Mr. Jean-Marc Bellemin M.B.A. (Age 50)
    Chief Financial Officer & Principal Accounting Officer
    Comp: $623.6k
  • Dr. Igor P. Bilinsky (Age 49)
    Chief Operating Officer
    Comp: $577.35k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 55)
    Chief Medical Officer
    Comp: $649.13k
  • Ms. Sara Pellegrino
    VP of Investor Relations & PR
  • Ms. Tracy Winton
    Sr. VP of HR
  • Mr. Howard B. Johnson M.B.A. (Age 62)
    Chief Bus. Officer
  • Mr. James Ziegler M.B.A.
    Exec. VP of Commercial
  • Mr. Madan Jagasia
    Exec. VP of Medical Affairs
  • Dr. Raj K. Puri M.D.
    Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2022?

10 Wall Street research analysts have issued 1-year price targets for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $13.00 to $43.00. On average, they anticipate the company's stock price to reach $23.80 in the next year. This suggests a possible upside of 143.1% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2022?

Iovance Biotherapeutics' stock was trading at $19.09 at the beginning of 2022. Since then, IOVA stock has decreased by 48.7% and is now trading at $9.79.
View the best growth stocks for 2022 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.03. During the same period in the prior year, the business earned ($0.53) EPS.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (7.49%), Franklin Resources Inc. (3.29%), Price T Rowe Associates Inc. MD (2.77%), Pictet Asset Management SA (2.31%), ARK Investment Management LLC (1.87%) and Sumitomo Mitsui Trust Holdings Inc. (1.78%). Insiders that own company stock include Frederick G Vogt and Merrill A Mcpeak.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $9.79.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.54 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 319 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.